DFX Intelligence

Data Factory

VentureFirmmicro vc · probableexempt_reporting_adviser

Healthcap Ix Advisor Ab

Venture Capital

Stockholm

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:a24345c3-7c27-4dd4-9a36-48e990ce9e20

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 4:48 PM UTC and rebuilt at most every 15 minutes.

Relationships: 68
Dated events: 9
On other graphs: 0
Observed: Sep 12, 2026 to Sep 17, 2026
33 observations

Across DFX

This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 1
Reported GAV: $3.4Mgross asset value on Form ADV; never dry powder
Funds with fundraising evidence: 0derived
Investments: 38
Portfolio companies: 38
Investments, 12m: 38
Partner-attributed: 0
People: 26
Investment professionals: 23derived
Co-investors: 0derived
LP relationships: 0
Stated sectors: healthcare,biotech,climate,mediaas stated by the firm
Stated geography: global,globally
Latest ADV filing: Mar 28, 2024
Website: healthcap.eufirm website, corroborated by Form ADV

Funds

Fund	Vintage	Lifecycle	Form D sold	GAV	LPs
Healthcap Ix D Ab	n/a	Unknown	n/a	$3.4M	0

Investments

round size is never this investor's check

Company	State	Stage	Round size	Partner	Attribution	Observed
AMRA Medical AB	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Aprea Therapeutics, Inc.	Pa	n/a	n/a	n/a	Unknown	Sep 16, 2026
Ariceum Therapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Bonesupport AB	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
CurifyLabs	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Doctrin	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Elsa	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Fusion Pharmaceuticals Inc.	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Gesynta Pharma	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
HelloBetter	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Hemab Therapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Incardatherapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Intervacc	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Kivu Bioscience	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Mahzi Therapeutics Inc.	CA	n/a	n/a	n/a	Unknown	Sep 16, 2026
Neobiomics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Oncopeptides AB	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Oncorena	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Positrigo	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Priothera Ltd.	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
chemotherapy	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
topoisomerase II	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
pyrimidine	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
analog	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
caused by human papillomavirus (HPV)	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026

Relationships

Member of firm (1)

→ Healthcap Advisor AbFirmRegistered domain redirects
inferenceForm ADV

Invested in (38)

→ topoisomerase IICompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ chemotherapyCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ OnQ™ Aerosol GeneratorCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Vivet TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Vicore PharmaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ SynOx Therapeutics LtdCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ DoctrinCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ ElsaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Fusion Pharmaceuticals Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Gesynta PharmaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ HelloBetterCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Hemab TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ IncardatherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ IntervaccCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Kivu BioscienceCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Mahzi Therapeutics Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ NeobiomicsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Oncopeptides ABCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ OncorenaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ PositrigoCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Priothera Ltd.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Spruce Biosciences, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ analogCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ caused by human papillomavirus (HPV)CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Adcendo ApSCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ AMRA Medical ABCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Aprea Therapeutics, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Ariceum TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Bonesupport ABCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ pyrimidineCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
and 8 more

Employs (25)

→ Thomas RamdahlPersonDirector, GP | MSc PhD
factThe subject's own site
→ Max OdlanderPersonPartner | MSc
factThe subject's own site
→ Alex ValcuPersonPartner | MSc
factThe subject's own site
→ Daniel KarsbergPersonPartner | MSc
factThe subject's own site
→ Anki ForsbergPersonPartner and Chairman | LLM MBA
factThe subject's own site
→ Carl-Johan DalsgaardPersonVenture Partner | MD PhD
factThe subject's own site
→ Kristina EkbergPersonDirector
Sep 1, 2022 to presentfactForm ADV, The subject's own site
→ Carl KilanderPersonPartner | MD PhD
factThe subject's own site
→ Johan ChristensonPersonPartner | MD PhD
factThe subject's own site
→ Staffan LindstrandPersonPartner | MSc
factThe subject's own site
→ Eugen SteinerPersonVenture Partner | MD PhD
factThe subject's own site
→ Georg Vo BeiskePersonVenture Partner | MSc
factThe subject's own site
→ Shamim DadvarPersonAssociate | MD PhD
factThe subject's own site
→ Josefine PerssonPersonAssociate | MSc
factThe subject's own site
→ Nikolai PausPersonAssociate I BSc
factThe subject's own site
→ Nima BaratiPersonMedical Associate I MD
factThe subject's own site
→ Marile SchiessPersonHead of Compliance I MSc
factThe subject's own site
→ Sofie WennerqvistPersonInvestment Monitor
factThe subject's own site
→ Nattiya SimmanoPersonOffice Manager
factThe subject's own site
→ Oern R. StugePersonDirector I MD MBA
factThe subject's own site
→ Fabrice BernhardPersonGeneral Manager | MSc
factThe subject's own site
→ Vanessa MalierPersonDirector, GP | MSc
factThe subject's own site
→ Per SamuelssonPersonPartner | MSc
factThe subject's own site
→ Marten SteenPersonDirector
Apr 1, 2023 to presentfactForm ADV
→ Bjorn OdlanderPersonDirector
Apr 1, 2023 to presentfactForm ADV

Manages (1)

→ Healthcap Ix D AbFundVenture Capital Fund
Mar 28, 2024 to presentfactForm ADV

Owns (1)

← Healthcap Ix Holding AbFirmDirect Owner
May 1, 2023 to presentfactForm ADV

Dated events

8 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Mar 28, 2024
Adviser's first ADV filing
Healthcap Ix Advisor Ab first filed Form ADV (ERA)
Form ADVobserved 7 days ago

Show 8 bookkeeping events

First seen by DFX
Sep 17, 2026
date not stated
myelodysplastic syndrome no longer listed on Healthcap Ix Advisor Ab's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
pulmonary embolism no longer listed on Healthcap Ix Advisor Ab's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
anthracycline extravasation no longer listed on Healthcap Ix Advisor Ab's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
low molecular weight heparin no longer listed on Healthcap Ix Advisor Ab's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
deep vein thrombosis no longer listed on Healthcap Ix Advisor Ab's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
heparin-induced thrombocytopenia no longer listed on Healthcap Ix Advisor Ab's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Howtogetridofwartshome no longer listed on Healthcap Ix Advisor Ab's portfolio page
Occurred
Mar 28, 2024
Healthcap Ix D Ab first reported on Form ADV by Healthcap Ix Advisor Ab (Venture Capital Fund), GAV $3,440,917

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 2 websites (Form ADV), 2 work emails (firm website) · as of 2026-09-17

Also named here, with no published line of their own (reach them through the firm): Thomas Ramdahl (Director, GP | MSc PhD), Max Odlander (Partner | MSc), Alex Valcu (Partner | MSc), Daniel Karsberg (Partner | MSc), Anki Forsberg (Partner and Chairman | LLM MBA), Carl-Johan Dalsgaard (Venture Partner | MD PhD), Kristina Ekberg (Director), Carl Kilander (Partner | MD PhD), Johan Christenson (Partner | MD PhD), Staffan Lindstrand (Partner | MSc), Eugen Steiner (Venture Partner | MD PhD), Georg Vo Beiske (Venture Partner | MSc).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance